{"id":"simulect","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Gastrointestinal disorders","drugRate":"69%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Viral infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperkalemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypokalemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperglycemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypercholesterolemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypophosphatemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperuricemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Sepsis","drugRate":"","severity":"serious"},{"effect":"Cardiac failure","drugRate":"","severity":"serious"},{"effect":"GI hemorrhage","drugRate":"","severity":"serious"},{"effect":"Thrombosis","drugRate":"","severity":"serious"},{"effect":"Bone fracture","drugRate":"","severity":"serious"},{"effect":"Atrial fibrillation","drugRate":"","severity":"serious"},{"effect":"Hemorrhage","drugRate":"","severity":"serious"},{"effect":"Esophagitis","drugRate":"","severity":"serious"},{"effect":"Angina pectoris","drugRate":"","severity":"serious"},{"effect":"Diabetes mellitus","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1201439","moleculeType":"Antibody"},"aliases":["Basiliximab","basiliximab","Simulect IV 40 mg/day D0 and D4","and oral use Tacrolimus 0.1 mg/ kg/ day +","Myfortic 720 to 1440mg +"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Simulect","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:02:19.156367+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:02:24.171240+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simulect","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:02:24.539905+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-2 receptor inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:02:25.594781+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201439/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:02:25.251049+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"1af01887-b69d-444b-91ed-ebfe12784440","title":"SIMULECT (BASILIXIMAB) INJECTION, POWDER, FOR SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]"},"ecosystem":[],"mechanism":{"target":"Interleukin-2 receptor subunit alpha"},"_scrapedAt":"2026-03-28T00:08:04.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:02:27.126963+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Renal transplant rejection","diseaseId":"renal-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT01780844","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-03-05","conditions":"Kidney Transplantation","enrollment":149},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":"Myeloma","enrollment":30},{"nctId":"NCT06374095","phase":"","title":"1 vs 7 RATG Infusions in Renal Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2024-07-30","conditions":"Kidney Replacement","enrollment":75},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT05139004","phase":"PHASE1","title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-19","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT02342145","phase":"PHASE4","title":"Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major","status":"COMPLETED","sponsor":"Zhongming Zhang","startDate":"2015-04","conditions":"Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)","enrollment":205},{"nctId":"NCT04736381","phase":"","title":"Impact of the Microbiota on the Likelihood of Renal Graft Rejection","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2021-10-07","conditions":"Kidney Transplant Rejection","enrollment":70},{"nctId":"NCT01476839","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-11-09","conditions":"Recurrent Adult Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT02342782","phase":"PHASE1","title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-06-08","conditions":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03478215","phase":"PHASE2","title":"Mesenchymal Stromal Cells in Living Donor Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2016-12","conditions":"Renal Transplantation, Mesenchymal Stem Cells","enrollment":24},{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT03031470","phase":"PHASE2","title":"Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2015-03-10","conditions":"Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction","enrollment":40},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT00717470","phase":"PHASE4","title":"A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05-14","conditions":"Kidney Transplantation","enrollment":1252},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01304836","phase":"PHASE4","title":"A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-22","conditions":"Kidney Transplantation","enrollment":1166},{"nctId":"NCT01002339","phase":"PHASE4","title":"Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation","status":"TERMINATED","sponsor":"Armando Torres Ramírez","startDate":"2010-02","conditions":"Diabetes Mellitus, Adult-Onset","enrollment":134},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT06480630","phase":"PHASE2","title":"Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-07-01","conditions":"Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm","enrollment":39},{"nctId":"NCT03794492","phase":"PHASE4","title":"Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-03-31","conditions":"Kidney Transplant","enrollment":169},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02464878","phase":"PHASE2","title":"Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Kidney Transplant, Type 1 Diabetes","enrollment":2},{"nctId":"NCT00752479","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2008-05","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT06087003","phase":"","title":"Pediatric Induction Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Gang Chen","startDate":"2013-03-03","conditions":"Kidney Transplant Rejection, Pediatric Kidney Disease","enrollment":958},{"nctId":"NCT06066840","phase":"PHASE4","title":"Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-08-01","conditions":"Safety and Efficacy","enrollment":45},{"nctId":"NCT05385432","phase":"PHASE3","title":"Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-09-12","conditions":"Renal Transplant Rejection, Induction Therapy","enrollment":244},{"nctId":"NCT02409147","phase":"NA","title":"Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-01","conditions":"Uterus Transplant","enrollment":""},{"nctId":"NCT02366728","phase":"PHASE2","title":"DC Migration Study for Newly-Diagnosed GBM","status":"COMPLETED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2015-10-12","conditions":"Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma","enrollment":64},{"nctId":"NCT04738981","phase":"PHASE3","title":"Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2021-02-01","conditions":"Graft Vs Host Disease","enrollment":130},{"nctId":"NCT02123108","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-01","conditions":"Liver Transplantation","enrollment":59},{"nctId":"NCT02730715","phase":"","title":"Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2010-11","conditions":"KIDNEY TRANSPLANTATION","enrollment":30},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT05021276","phase":"PHASE4","title":"Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-12-15","conditions":"Safety and Efficacy","enrollment":50},{"nctId":"NCT05013034","phase":"PHASE2","title":"Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients","status":"UNKNOWN","sponsor":"Fort Worth Clinical Sciences Working Group","startDate":"2021-10-15","conditions":"SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection, Cytokine Storm","enrollment":300},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT00626483","phase":"PHASE1","title":"Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia","status":"COMPLETED","sponsor":"Gary Archer Ph.D.","startDate":"2007-04-24","conditions":"Malignant Neoplasms Brain","enrollment":34},{"nctId":"NCT04404127","phase":"PHASE4","title":"Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2020-09-01","conditions":"Kidney Transplantation","enrollment":140},{"nctId":"NCT02523768","phase":"PHASE4","title":"Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2011-01-08","conditions":"Glomerulonephritis, IgAN","enrollment":117},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT00492869","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":124},{"nctId":"NCT00403416","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Kidney Transplantation","enrollment":215},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT01387659","phase":"NA","title":"Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2011-03","conditions":"Diabetes, Immunosuppression","enrollment":2},{"nctId":"NCT04337593","phase":"PHASE2","title":"Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2020-06-01","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":20},{"nctId":"NCT01120028","phase":"PHASE2, PHASE3","title":"Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-09","conditions":"Kidney Transplantation","enrollment":852},{"nctId":"NCT01453218","phase":"PHASE3","title":"Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction","status":"COMPLETED","sponsor":"Hospital Vall d'Hebron","startDate":"2011-10","conditions":"Renal Insufficiency","enrollment":30},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT03006419","phase":"PHASE4","title":"Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2016-12-01","conditions":"Kidney Transplant Rejection, Kidney Transplant; Complications","enrollment":100},{"nctId":"NCT01136395","phase":"PHASE2","title":"Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2010-01","conditions":"Kidney Transplantation, Rituximab (RTx), Living Donors","enrollment":85},{"nctId":"NCT00434811","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT02723786","phase":"PHASE2","title":"Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-08-27","conditions":"Kidney Transplantation (Status Post)","enrollment":7},{"nctId":"NCT01660529","phase":"EARLY_PHASE1","title":"Multi-peptide Vaccine With Basilixumab for Breast Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2012-06","conditions":"Metastatic Breast Cancer","enrollment":10},{"nctId":"NCT01649427","phase":"PHASE4","title":"Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-17","conditions":"Pharmacokinetics Study in de Novo Kidney Transplantation","enrollment":73},{"nctId":"NCT01485055","phase":"PHASE2","title":"Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease","status":"TERMINATED","sponsor":"Nationwide Children's Hospital","startDate":"2011-12","conditions":"Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease","enrollment":11},{"nctId":"NCT01541176","phase":"PHASE4","title":"Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-04","conditions":"Renal Transplant","enrollment":193},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT03789006","phase":"PHASE4","title":"Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation","status":"UNKNOWN","sponsor":"University of Khartoum","startDate":"2018-03-21","conditions":"Kidney Transplant Rejection","enrollment":300},{"nctId":"NCT02328963","phase":"PHASE4","title":"Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-05-02","conditions":"Transplantation Infection, Cytomegalovirus Infection","enrollment":186},{"nctId":"NCT02957552","phase":"PHASE1","title":"Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2017-03-10","conditions":"Pediatric Liver Transplantation","enrollment":7},{"nctId":"NCT00154284","phase":"PHASE3","title":"Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Organ Transplantation, Renal Transplantation","enrollment":114},{"nctId":"NCT01842139","phase":"PHASE1","title":"Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-12-05","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":7},{"nctId":"NCT00888628","phase":"PHASE1, PHASE2","title":"Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-05","conditions":"Diabetes Mellitus, Type I","enrollment":7},{"nctId":"NCT02056938","phase":"PHASE4","title":"ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2014-06","conditions":"Kidney Transplantation","enrollment":19},{"nctId":"NCT01884571","phase":"PHASE2","title":"Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-10","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":31},{"nctId":"NCT00468117","phase":"PHASE3","title":"Efficacy of Islet After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT00729768","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation","status":"WITHDRAWN","sponsor":"Genentech, Inc.","startDate":"","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT03192657","phase":"PHASE2","title":"Basiliximab Treating Interstitial Pneumonia of CADM","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-07","conditions":"Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis","enrollment":100},{"nctId":"NCT03171831","phase":"PHASE4","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-04-01","conditions":"Thalassemia Major","enrollment":30},{"nctId":"NCT00188825","phase":"PHASE3","title":"Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2004-05","conditions":"COPD, Emphysema, Alpha-1 Antitrypsan Deficiency","enrollment":22},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00284947","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-01","conditions":"Kidney Transplantation, Adverse Effects","enrollment":7},{"nctId":"NCT00369161","phase":"PHASE4","title":"A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-06","conditions":"Renal Transplantation","enrollment":228},{"nctId":"NCT00820911","phase":"PHASE2","title":"Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Transplantation","enrollment":175},{"nctId":"NCT00229138","phase":"PHASE4","title":"Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Kidney Transplantation","enrollment":291},{"nctId":"NCT02843841","phase":"NA","title":"Polyclonal Antilymphocyte Globulin (ATG) & Intestinal Immune Barrier After Kidney Transplantation","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2014-12","conditions":"Disorder Related to Renal Transplantation","enrollment":63},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT03005236","phase":"PHASE4","title":"AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation","status":"UNKNOWN","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2017-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT00504543","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":311},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT02894606","phase":"","title":"Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2015-02","conditions":"Renal Transplant","enrollment":40},{"nctId":"NCT02558452","phase":"","title":"European Transplant Registry of Senior Renal Transplant Recipients on Advagraf","status":"NOT_YET_RECRUITING","sponsor":"Klemens Budde","startDate":"2016-12","conditions":"Graft Failure, Death, Acute Rejection of Renal Transplant","enrollment":1000},{"nctId":"NCT01336296","phase":"PHASE4","title":"Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2010-09","conditions":"Kidney Transplant Recipients","enrollment":61},{"nctId":"NCT02770430","phase":"PHASE2","title":"Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2015-09","conditions":"Graft vs Host Disease","enrollment":90},{"nctId":"NCT01625377","phase":"PHASE3","title":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Liver Transplantation","enrollment":188},{"nctId":"NCT00859131","phase":"NA","title":"Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-03","conditions":"End Stage Renal Disease","enrollment":200},{"nctId":"NCT00464555","phase":"PHASE2","title":"Strategies to Improve Islet Survival","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-12","conditions":"Type 1 Diabetes Mellitus","enrollment":5},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""},{"nctId":"NCT00468403","phase":"PHASE2","title":"LEA29Y (Belatacept) Emory Edmonton Protocol","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-10","conditions":"Type 1 Diabetes Mellitus","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1201439"},"formularyStatus":[],"_approvalHistory":[{"date":"20010323","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA103764"},{"date":"20030527","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA103764"},{"date":"20031114","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA103764"},{"date":"20010322","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA103764"},{"date":"20011129","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA103764"},{"date":"20050915","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA103764"},{"date":"19980512","type":"ORIG","sponsor":"NOVARTIS","applicationNumber":"BLA103764"},{"date":"20030102","type":"SUPPL","sponsor":"NOVARTIS","applicationNumber":"BLA103764"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":113,"therapeuticAreas":["Nephrology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Simulect","genericName":"Simulect","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:02:27.126963+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}